FourThought Financial’s Ligand Pharmaceuticals LGND Stock Holding History

FourThought Financial’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$16K	Hold	301	–	–	﹤0.01%	920
2022 Q2	$17K	Sell	301 -129	-30%	-$7.32K	﹤0.01%	900
2022 Q1	$30K	Hold	430	–	–	﹤0.01%	807
2021 Q4	$41K	Hold	430	–	–	0.01%	724
2021 Q3	$37K	Hold	430	–	–	﹤0.01%	778
2021 Q2	$35K	Hold	430	–	–	﹤0.01%	810
2021 Q1	$40K	Sell	430 -141	-25%	-$13.3K	0.01%	742
2020 Q4	$35K	Buy	+571	New	+$32.6K	0.01%	748

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

FourThought Financial's LGND Position: Q3 2022 in Review

FourThought Financial held its Ligand Pharmaceuticals (LGND) position steady in Q3 2022 at 301 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #920.

FourThought Financial first reported a position in LGND in Q4 2020 and has held it in 8 quarters since. The position peaked at $41K in Q4 2021. 205 funds tracked by Wall St. Rank hold LGND as of Q3 2022.

FourThought Financial held 301 shares of Ligand Pharmaceuticals worth $16K as of Q3 2022.
FourThought Financial left its Ligand Pharmaceuticals share count unchanged in Q3 2022.
Ligand Pharmaceuticals made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #920 holding.
FourThought Financial first reported a position in Ligand Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Ligand Pharmaceuticals position peaked at $41K in Q4 2021.
205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.